Quoin Pharmaceuticals, Ltd.
QNRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.01 | 0.01 | -0.00 |
| FCF Yield | -9,013.81% | -177.79% | -126.86% | -87.99% |
| EV / EBITDA | 0.07 | -0.60 | -0.95 | -34.79 |
| Quality | ||||
| ROIC | -0.08% | -102.34% | -72.98% | -2.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.91 | 0.90 | 0.27 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.09% | 9.92% | -37.60% | -333.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | -0.12 | -0.15 | -34.45 |
| Interest Coverage | 0.00 | 0.00 | -11.78 | -18.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -3,290.22 | -1,857.93 | -2,132.91 | -3,236.63 |